For the quarter ending 2025-09-30, ZVSA had $455,892 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Non-cash rent expense | - | 0 |
| Net loss | -19,805,559 | -4,468,247 |
| Impairment of in-process research and development | 18,647,903 | - |
| Stock-based compensation | 73,988 | 131,490 |
| Depreciation of fixed assets | - | 0 |
| Issuance of common stock pursuant to vendor agreements | 29,600 | 210,400 |
| Deferred tax (benefit) provision | -851,659 | 0 |
| Prepaid expenses and other current assets | -80,557 | 193,876 |
| Accounts payable | 314,798 | 56,208 |
| Operating lease liability | - | 0 |
| Vendor deposits | -1,652 | 8,700 |
| Accrued expenses and other current liabilities | 105,112 | 961,545 |
| Net cash used in operating activities | -1,406,912 | -3,293,780 |
| Exercise of warrants | - | 0 |
| Private placement of warrants | 0 | 1,999,791 |
| Warrant inducement offer - exercise proceeds | 2,051,852 | - |
| Exercise of pre-funded warrants | 0 | 210 |
| Deferred offering costs | 12,511 | 17,928 |
| Registration and issuance costs associated with warrant issuance | 219,487 | 147,131 |
| Net cash provided by financing activities | 1,862,804 | 1,834,942 |
| Net decrease in cash | 455,892 | -1,458,838 |
| Cash and cash equivalents at beginning of period | 1,530,924 | - |
| Cash and cash equivalents at end of period | 527,978 | - |
ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. (ZVSA)